AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

⟵ Back to Search Results

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Beigene Study ID

BGB-A317-A1217-202 AdvanTIG-202

ClinicalTrials.gov ID

NCT04693234

EudraCT Number

2020-004657-77

Study Overview

Sex: Female

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: Female

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

You will be redirected to

Click the link above to continue or CANCEL